Special NoticePosted Aug 19, 2026·Responses due Aug 26, 2026

Leptin Protein (26-006897)

National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO

Stage
Early notice (sources sought, presolicitation or special notice)
NAICS
325414
Value
Not stated
Solicitation
26-006897
Set-aside
No Set aside used
PSC
6505
Place
Bethesda, MD, USA
Contact
Gregory Noland (gregory.noland@nih.gov)
Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 26-006897 in this department, oldest first.

Early notice
  • Aug 19, 2026 · this notice
    Special Notice
Solicitation
None posted
Award
Not yet. Typical award: Sep 28, 2026 to Jun 20, 2027, middle of the range Oct 22, 2026.
Measured from 68 past early notices at National Institutes of Health that later posted an award (middle half of cases, counted from Aug 19, 2026).

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Answer the notice: this is when the requirement can still be shaped.
  • Contact the contracting officer named on the notice.
  • Check who won similar work; they are the likely bidders.

What the notice says

The National Institute of Health (NIH) intends to negotiate and award a purchase order without providing for full and open competition to BIO-TECHNE SALES CORP. The purpose of this requirement is to provide a firm-fixed-price contract for Recombinant Rat Leptin Protein in the Critical Care Medicine Department within the NIH Clinical Center. The Critical Care Medicine Department conducts active research programs in bedside clinical investigation, research in animal models, and molecular biology. Full-time research activities commence at the beginning of the second year of the fellowship for fel… (show all)

lows interested in the critical care subspecialty alone. For those interested in dual board eligibility, their second-year program is individually designed and consists of clinical rotations required for board eligibility in the particular subspecialties. After completion of second subspecialty training, full-time research activities commence. Major topics of research interest within the Department include: The immunopathogenesis of septic shock Studies of immune cellular function in respiratory distress syndrome, asthma, and other forms of severe pulmonary disease Biomarkers and novel therapies in pulmonary arterial hypertension Biomarkers of acute cellular rejection in heart transplantation Diagnosis and treatment of opportunistic infections Studies of immune cellular function and therapy of AIDS Pathogenesis and treatment of anthrax Emerging infectious diseases Biology and clinical effects of nitric oxide acute lung injury pulmonary arterial hypertension role as transcription regulatory factor Functional genomics of critical illness human acute inflammation animal model of septic shock and multiple organ failure pulmonary arterial hypertension solid organ transplantation Emerging Infectious Disease This product is a sole source item as it�s manufactured by the supplier. This material will be use on in vivo experiment under ORWH Innovation Awards SEX- AND OBESITY-ASSOCIATED MECHANISMS AND THERAPEUTIC TARGETS IN PULMONARY ARTERIAL HYPERTENSION. Biological material for animal treatments can�t be changed as we will incur in additional testing, additional testing subjects and validation and in vivo results can�t be compared. Finally, a review of the GSA Advantage, Dynamic Small Business Search, and previous government acquisitions returned no results that meet all of the requirements. Therefore, only BIO-TECHNE SALES CORP. is capable of meeting the needs of this requirement.

Who won similar work

3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) 6505.

Single-winner award sizes (3): middle half $82K to $470K, median $137K; range $28K to $804K.

WinnerAwardsValueLast
VECTOR BIOMED INC.1$804KDec 2, 2024
PACIFIC BIOSCIENCES OF CALIFORNIA, INC · $PACB · $200.5M1$137KNov 19, 2024
10X GENOMICS, INC. · $TXG · $618.7M1$28KDec 20, 2024

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $PACB reported $200.5M revenue in FY2025. The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. 10-K
  • $TXG reported $618.7M revenue in FY2025. The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. 10-K

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Competitive landscape

For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
  • 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
  • No corporate PAC money from them to the overseeing committees since 2024
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 0 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 2 of the past winners are listed companies
  • 0 insider buys and 5 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.